This proposal describes a multidisciplinary approach to the study of brain tumors for the eventual establishment of a brain tumor research center. Such a center would facilitate an environment optimizing collaboration between laboratory scientists and clinical investigators united in a common goal to improve the management of patients with brain tumors. A unifying theme and overall goal is the clinical applicability of the studies proposed under the auspices of the brain tumor research center with the premise that academic interaction between scientists and clinicians will lead to more expeditious vertical transfer of ideas and methods. Individual projects utilize a central core for handling and blanking of tissue and assimilation of clinical and experimental data. Specific projects include studies to improve diagnosis and classification of brain tumors through analysis of tumor-related gene expression, frequency of DNA loss, advanced sodium magnetic resonance imaging and proton spectroscopy, and detailed histological analysis. Other studies with potential therapeutic implications include investigations with oligonucleotides, taxol, and recombinant autoantibodies. Basic science projects investigate factors controlling tumor invasion and the role of protein kinase C in controlling growth and tumorigenesis.
| Begemann, M; Kashimawo, S A; Heitjan, D F et al. (1998) Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. Anticancer Res 18:2275-82 |
| Venkatraj, V S; Begemann, M; Sobrino, A et al. (1998) Genomic changes in glioblastoma cell lines detected by comparative genomic hybridization. J Neurooncol 36:141-8 |
| Begemann, M; Kashimawo, S A; Lunn, R M et al. (1998) Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. Anticancer Res 18:3139-52 |
| Begemann, M; Kashimawo, S A; Choi, Y A et al. (1996) Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clin Cancer Res 2:1017-30 |
| Moulton, T; Samara, G; Chung, W Y et al. (1995) MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146:613-9 |
